Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	384.75M -36.6%
Revenue (ttm)	170.16M -25.1%
Net Income	-312.76M
EPS	-5.64
Shares Out	58.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	819,470
Open	6.36
Previous Close	6.50
Day's Range	6.30 - 6.68
52-Week Range	5.00 - 17.58
Beta	1.59
Analysts	Hold
Price Target	10.50 (+58.85%)
Earnings Date	Feb 26, 2026

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 485
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgo.bio

Financial Performance

In 2025, Ginkgo Bioworks Holdings's revenue was $170.16 million, a decrease of -25.06% compared to the previous year's $227.04 million. Losses were -$312.76 million, -42.83% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for DNA stock is "Hold." The 12-month stock price target is $10.5, which is an increase of 58.85% from the latest price.

Price Target

$10.5

(58.85% upside)

Analyst Consensus: Hold